Counterpoint - The vision for a new diagnostic paradigm

被引：59

作者：

Petricoin, E

Liotta, LA

机构：

[1] NCI, NCI FDA Clin Proteom Program, Pathol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA

[2] NCI, FDA Clin Proteom Program, Off Direct, Ctr Biol Evaluat & Res Food & Drug Adm, Bethesda, MD 20892 USA

来源：

关键词：

PROTEOMIC PATTERNS; SERUM; BIOMARKER; PROSTATE; IDENTIFICATION;

D O I：

10.1373/49.8.1276

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

[No abstract available]

引用

页码：1276 / 1278

页数：3

共 13 条

[1] Adam BL, 2001, PROTEOMICS, V1, P1264, DOI 10.1002/1615-9861(200110)1:10<1264::AID-PROT1264>3.0.CO
[2] 2-R
[3] Adam BL, 2002, CANCER RES, V62, P3609
[4] The human plasma proteome - History, character, and diagnostic prospects
Anderson, NL
Anderson, NG
[J]. MOLECULAR & CELLULAR PROTEOMICS, 2002, 1 (11) : 845 - 867
[5] Mass spectrometry in the clinical laboratory
Chace, DH
[J]. CHEMICAL REVIEWS, 2001, 101 (02) : 445 - 477
[6] CHASE KTA, 2002, ANNU REV GENOM HUM G, V3, P17
[7] Human kallikrein 6 (hK6): A new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma
Diamandis, EP
Scorilas, A
Fracchioli, S
van Gramberen, M
de Bruijn, H
Henrik, A
Soosaipillai, A
Grass, L
Yousef, GM
Stenman, UH
Massobrio, M
van der Zee, AGJ
Vergote, I
Katsaros, D
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (06) : 1035 - 1043
[8] Osteopontin as a potential diagnostic biomarker for ovarian cancer
Kim, JH
Skates, SJ
Uede, T
Wong, KK
Schorge, JO
Feltmate, CM
Berkowitz, RS
Cramer, DW
Mok, SC
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13): : 1671 - 1679
[9] Li JN, 2002, CLIN CHEM, V48, P1296
[10] Petricoin EF, 2002, J NATL CANCER I, V94, P1576